All In Biotech

Drug Trial Radar · NCT05400317

A Study to Evaluate the Efficacy and Safety of AD-218

A Randomized, Double-blinded, Active-controlled, Multicenter Phase 3 Clinical Trial and Open-label, Extension Study to Evaluate the Efficacy and Safety of AD-218 in Patients with Mixed Dyslipidemia

Last checked: Nov 19, 2026Latest source record: Feb 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 520 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

520

Planned (sponsor's estimate)

Start

Jul 27, 2022

Primary completion

Mar 31, 2026

Study completion Jun 30, 2026

Sponsor

Lead sponsor
Addpharma Inc.Industry
Sponsor type
Industry
First posted
Jun 1, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of AD-218

Conditions

  • Mixed Dyslipidemia

Interventions

  • AD-218Drug

    PO, Once daily(QD), 12weeks

  • AD-218ADrug

    PO, Once daily(QD), 12weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change (%) of non-HDL-C from baseline at week 12Time frame: from baseline at 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Yeongnam University Hospital

    Daegu, Nam-gu, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.